Barclays PLC Buys 23,738 Shares of Pulse Biosciences, Inc. (NASDAQ:PLSE)

Barclays PLC boosted its position in Pulse Biosciences, Inc. (NASDAQ:PLSE) by 361.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,306 shares of the company’s stock after buying an additional 23,738 shares during the period. Barclays PLC’s holdings in Pulse Biosciences were worth $530,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. increased its holdings in shares of Pulse Biosciences by 193.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company’s stock valued at $2,598,000 after acquiring an additional 97,565 shares in the last quarter. State Street Corp lifted its holdings in shares of Pulse Biosciences by 17.8% in the 3rd quarter. State Street Corp now owns 461,333 shares of the company’s stock worth $8,092,000 after purchasing an additional 69,696 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Pulse Biosciences in the 3rd quarter valued at $588,000. Creative Planning increased its stake in Pulse Biosciences by 113.9% during the 3rd quarter. Creative Planning now owns 21,910 shares of the company’s stock valued at $384,000 after purchasing an additional 11,667 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its stake in Pulse Biosciences by 23.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company’s stock valued at $570,000 after purchasing an additional 9,639 shares in the last quarter. 76.95% of the stock is owned by institutional investors and hedge funds.

Pulse Biosciences Price Performance

Shares of PLSE opened at $17.79 on Friday. The stock has a 50 day moving average price of $18.02 and a two-hundred day moving average price of $16.90. Pulse Biosciences, Inc. has a 52 week low of $6.59 and a 52 week high of $22.69.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share (EPS) for the quarter. During the same period last year, the company posted ($0.19) earnings per share.

Insider Activity at Pulse Biosciences

In related news, CEO Burke Thomas Barrett sold 50,000 shares of the business’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $17.42, for a total value of $871,000.00. Following the transaction, the chief executive officer now directly owns 63,172 shares of the company’s stock, valued at approximately $1,100,456.24. The trade was a 44.18 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Robert W. Duggan acquired 55,256 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The shares were bought at an average price of $17.18 per share, with a total value of $949,298.08. Following the acquisition, the director now directly owns 42,328,717 shares of the company’s stock, valued at $727,207,358.06. The trade was a 0.13 % increase in their position. The disclosure for this purchase can be found here. 71.50% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Separately, StockNews.com raised shares of Pulse Biosciences to a “sell” rating in a research note on Thursday.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.